Many cancer patients are not eligible for surgery or radiation therapy due to increased risk factors such as old age, poor health, and other medical conditions. These people often do not survive past five years after diagnosis. One treatment that has shown promise in improving these survival rates is DCT (dendritic cell therapy). The DCT involves the production of autologous tumor lysate-pulsed dendritic cells which are then injected into the patient’s body where they stimulate an immune response against the cancer cells. This type of DCT has been used successfully with gastric and colorectal cancers, showing significant improvement in survival rates.
The most common adverse effect observed in all patients receiving DC/CIK therapy was fever, which occurred in 9 of 27 treated patients (33%) in the range of 37.5–40uC. All patients recovered spontaneously or after antipyretic treatment with non- steroid medicine. No other significant complications accompany- ing cell-based immunotherapy were observed.
Autologous tumor lysate-pulsed dendritic cell immunotherapy with cytokine-induced killer cells improves survival in gastric and colorectal cancer patients. Recent studies have shown that this type of treatment can increase the percentage of long term survivors by up to 80%. The therapy is used for people who are not candidates for surgery or conventional treatments, due to their advanced stages of cancer. This therapy has been successful in treating some tumors that were previously considered incurable.
Article Reference link: click here
Scientific article publishing date : 3/4/2014
Immucura identifier : BSC21_012EN